Inflammatory lung disease a potential risk factor for onset of idiopathic inflammatory myopathies: Results from a pilot study

RMD Open

Volumn 2, Issue 2, 2016, Pages

  Helmers, Sevim Barbasso ^a   Jiang, Xia ^a   Pettersson, David ^a   Wikman, Anna Lis ^b   Axelman, Pia ^a   Lundberg, Åsa ^b   Lundberg, Ingrid E ^b   Alfredsson, Lars ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85008686797     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2016-000342     Document Type: Article

References (15)

1. O'Hanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A,-B,-Cw,-DRB1, and-DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006;85:111-27
2. Chinoy H, Adimulam S, Marriage F, et al. Interaction of HLA-DRB1∗03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann Rheum Dis 2012;71:961-5
3. Hengstman GJ, van Venrooij WJ, Vencovsky J, et al. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis 2000;59:141-2
4. Azali P, Barbasso Helmers S, Kockum I, et al. Low serum levels of vitamin D in idiopathic inflammatory myopathies. Ann Rheum Dis 2013;72:512-6
5. Zampieri S, Ghirardello A, Iaccarino L, et al. Polymyositisdermatomyositis and infections. Autoimmunity 2006;39:191-6
6. Rider LG, Wu L, Mamyrova G, et al. Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2010;49:2381-90
7. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74
8. Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008;59:677-85
9. Chatham W. Rheumatic manifestations of systemic disease: sarcoidosis. Curr Opin Rheumatol 2010;22:85-90
10. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7
11. Stolt P, Bengtsson C, Nordmark B, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003;62:835-41
12. Bronner Intramuscular, van der Meulen MF, de Visser M, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006;65:1456-61
13. Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006;25:234-9
14. Eloranta ML, Barbasso Helmers S, Ulfgren AK, et al. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007;56:3112-24
15. Lundberg IE, Helmers SB. The type I interferon system in idiopathic inflammatory myopathies. Autoimmunity 2010;43:239-43.